WHEN THE TREATMENT OF A PATHOLOGY AGGRAVATES ANOTHER.TERBINAFINE AND PSORIASIS: TWO CASES REPORT
Journal: International Journal of Advanced Research (Vol.6, No. 9)Publication Date: 2018-09-08
Authors : Jawad El-Azhari Youssef Zemmez Naoufal Hjira; Mohammed Boui.;
Page : 125-128
Keywords : terbinafine psoriasis interleukin-23 (IL-23) latency..;
Abstract
Terbinafine is an allylamine having an in vitro fungicidal effect on dermatophytes and fungistatic on Candida albicans. It is an agent widely used in dermatology but also in general medicine and other specialties. It is, however, responsible of side effects in 10.5% of patients, mainly gastrointestinal and cutaneous. These cutaneous manifestations occur in 2.7% of patients in the form of erythema, urticaria, eczema, pruritus or rarely of alopecia areata. Cases of erythema multiforme / toxic epidermal necrolysis and Stevens-Johnson syndrome have been reported. We report the cases of two patients who had psoriasis lesions after taking oral terbinafine.
Other Latest Articles
- STRATEGIC IMPERATIVES OF ACT EAST POLICY OF INDIA
- VALIDITY OF CONE BEAM COMPUTED TOMOGRAPHY VOXEL DENSITY VALUES: A REVIEW
- OCCUPATIONAL HAZARD: NEEDLE STICK INJURY AMONG HEALTH CARE WORKERS
- EVALUATING QUALITY OF LIFE OF PATIENTS WITH VARICOSE VEIN
- PURSUING COMMON BUSINESS ETHICS: LEADING TOWARD GLOBAL COMMUNITY
Last modified: 2018-10-12 20:39:17